Kyntra Bio, Inc. (NASDAQ:KYNB) Q4 2025 Earnings Call Transcript March 16, 2026 Kyntra Bio, Inc. beats earnings expectations. Reported EPS is $-3.61, expectations were $-3.885. Operator: Thank you for ...

Kyntra Bio(NASDAQ:KYNB) reported that its rebranding, asset sale, and debt payoff have shifted the company’s financial structure and enabled a clinical focus on oncology and rare disease. Management ...

Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsRobert Eno - CEO, Chief Business Officer & ...

HeartBeam, Inc. (NASDAQ:BEAT) Q4 2025 Earnings Call Transcript March 12, 2026 HeartBeam, Inc. misses on earnings expectations. Reported EPS is $-0.15728 EPS, expectations were $-0.1375. Operator: ...

Good afternoon, and thank you for joining today's conference call to discuss Peraso Fourth Quarter and Full Year 2025 financial ...

AI is rapidly reshaping the landscape of surgical oncology. However, its true potential lies not in isolated tools, but ...

Earnings call CAREL Industries reported FY 2025 revenue of EUR 629 million, up 8.7% YoY (10.6% organic), with Q4 organic growth accelerating to 16.9%. Adjusted EBITDA margin reached 20%, and net ...

Detailed price information for Alphatec Holdings (ATEC-Q) from The Globe and Mail including charting and trades.

You drug them with? Netting bacteria in infectious mononucleosis develop into panic over nothing whatsoever. Magistrate coerce witness to interior lining.

We explore critical stages of M&A transactions and examine how AI is now available for deployment at each stage and the ...

AI-enabled platform auto-categorizes HER2 cases during scanning, allowing pathologists to review pre-analyzed results ...